Neurodegeneration: 2024 update

Overview

This review highlights impactful studies published in 2023-2024 across the neurodegenerative disease landscape. It covers topics ranging from chronic traumatic encephalopathy (CTE) in young athletes to AI-driven histological brain age estimation, cell-type-specific polygenic risk in Alzheimer’s, and the emerging link between viral exposures and neurodegenerative disease risk.

Core Thesis

Neurodegeneration is increasingly understood as a complex, non-cell-autonomous process involving immune system interactions (microglia/T-cells), environmental triggers (repetitive head impacts, viral infections), and cell-type-specific genetic vulnerabilities. Progress in digital pathology and AI is providing new tools for more precise diagnosis and understanding of brain aging.

Key Findings

1. CTE in Young Athletes

  • What was found: 41.4% of athletes younger than 30 with repetitive head impacts (RHI) showed neuropathological changes diagnostic for CTE (predominantly mild stages I or II).
  • Measurement: Analysis of 152 brain donors from the UNITE Brain Bank.
  • Strength of evidence: Strong (Large-scale brain bank study).

2. Viral Exposures and NDD Risk

  • What was found: Significant associations between viral exposures (e.g., viral encephalitis, influenza, EBV) and increased risk of neurodegenerative diseases (AD, ALS, MS, PD, VAS). Viral encephalitis showed the strongest association with AD risk.
  • Measurement: Large-scale biobank data from FinnGen and UK Biobank.
  • Strength of evidence: Moderate to Strong (Replicated across two major biobanks).

3. Cell-Type-Specific Polygenic Risk in AD

  • What was found: Astrocytic polygenic risk scores (ADPRS) are primarily associated with early amyloid-β (Aβ) accumulation, while microglial ADPRS are linked to both Aβ and tau pathologies, as well as cognitive decline.
  • Measurement: Integration of GWAS, snRNA-seq, and longitudinal clinical data (ROSMAP).
  • Strength of evidence: Moderate (Involves complex causal modeling).

4. Microglia-T cell Interaction

  • What was found: Tauopathy, but not amyloid deposition, triggers a unique adaptive immune response involving increased T-cells in regions with tau pathology. Microglia act as antigen-presenting cells to T-cells, promoting their infiltration.
  • Measurement: Mouse models and human AD brain tissue using scRNA-seq and scTCR-seq.
  • Strength of evidence: Moderate.

Mechanisms Proposed

Neuroinflammation and Adaptive Immunity

The review highlights that tau pathology specifically recruits T-cells, suggesting that the adaptive immune response is a key driver of neurodegeneration in tauopathies like AD and CTE. Microglia are central to this as they “present” antigens to T-cells.

Viral Priming

The “Viral Exposure” hypothesis: Early or severe viral infections may prime the central nervous system’s immune environment or directly damage neurons, lowering the threshold for developing NDDs later in life or accelerating existing pathologies.

What this paper adds

It synthesizes very recent (2023-2024) high-impact findings, particularly emphasizing that neurodegeneration begins much earlier than previously thought (e.g., CTE in youth) and is heavily influenced by systemic factors like viral history.

Limitations and Caveats

  • Biobank studies on viral links show association, not necessarily direct causality (though hazard ratios are high).
  • Many findings rely on post-mortem tissue, which represents the end-stage of disease.
  • Heterogeneity in human populations remains a challenge for AI-driven “brain age” models.

Open Questions

  • Can vaccination (e.g., for influenza or varicella-zoster) significantly reduce the population-level risk of Alzheimer’s and other NDDs?
  • How do we translate cell-type-specific genetic risk into targeted therapeutic interventions?
  • What are the earliest detectable biomarkers for CTE in living young athletes?

Updates to Wiki